FT counts 39 plants banned in India as regulatory woes mount for drugmakers
A hard drumbeat of U.S. FDA complaints against more than two dozen companies in India for quality violations has affected 39 drugmaking facilities, creating an avalanche of remedial work that could take years and is steadily driving up medicine costs in the United States. In a special report, the Financial Times detailed the cost in figures and prestige for a core industry in the country and one hailed by Prime Minister Narendra Modi as a key to boosting manufacturing jobs.Read more
A hard drumbeat of U.S. FDA complaints against more than two dozen companies in India for quality violations has affected 39 drugmaking facilities, creating an avalanche of remedial work that could take years and is steadily driving up medicine costs in the United States. In a special report, the Financial Times detailed the cost in figures and prestige for a core industry in the country and one hailed by Prime Minister Narendra Modi as a key to boosting manufacturing jobs.Read more
No comments:
Post a Comment